Clinical trial
Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma…
NCT00311857 · Heidelberg University, Other · Unknown status
Key facts
| NCT number | NCT00311857 |
|---|---|
| Title | Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT) |
| Official title | Treatment of Primary Glioblastoma Multiforme With Cetuximab, Radiotherapy and Temozolomide (GERT) - Phase I/II Trial |
| Lead sponsor | Heidelberg University, Other |
| Collaborators | Merck KGaA, Darmstadt, Germany Industry |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Glioblastoma Multiforme |
| Intervention type | Drug, Procedure |
| Interventions | Cetuximab, Temozolomide, Radiation therapy |
| Enrollment | 46 |
| Start date | Feb 1, 2006 |
| First posted | Apr 6, 2006 |
| Last update posted | Sep 8, 2006 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: